← Back to Analyst Consensus 
CNTB Buy
Connect Biopharma Holdings Ltd
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 3 reiterations from 2 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 30, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Sep 22, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Sep 17, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 16, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Sep 15, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jul 9, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Jun 26, 2026 | Piper Sandler | initiate | Neutral → Overweight | — | 54% |
| Jun 25, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 26, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| May 21, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Apr 1, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 31, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Dec 1, 2025 | Lake Street | initiate | — → Buy | $9 | 47% |
| Nov 13, 2025 | BTIG | reiterate | Buy → Buy | $10 | 52% |
| Oct 31, 2025 | BTIG | initiate | — → Buy | $10 | 52% |
| Aug 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $7 | 44% |
| Apr 1, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 31, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Sep 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jun 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Apr 17, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Mar 4, 2024 | HC Wainwright & Co. | initiate | — → Buy | $7 | 44% |
| Sep 13, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $5 | 50% |
| Feb 8, 2023 | SVB Leerink | maintain | — → Outperform | $7 | — |
| Jun 2, 2022 | Cantor Fitzgerald | initiate | — → Overweight | $5 | 50% |
| May 5, 2022 | Piper Sandler | downgrade | Overweight → Neutral | $1.5 | 54% |
| May 4, 2022 | SVB Leerink | maintain | — → Outperform | $9 | — |
| Jan 6, 2022 | SVB Leerink | maintain | — → Outperform | $22 | — |
| Apr 13, 2021 | Jefferies | initiate | — → Buy | $27 | 52% |
| Apr 13, 2021 | SVB Leerink | initiate | — → Outperform | $32 | — |
Price Target Trend
May 13, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days